Fennec Pharmaceuticals (NASDAQ:FENC) announced its earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), MarketWatch Earnings reports.
Shares of FENC stock opened at $6.01 on Thursday. Fennec Pharmaceuticals has a 12 month low of $5.33 and a 12 month high of $14.99. The company has a market cap of $136.29 million, a PE ratio of -12.79 and a beta of -0.23.
A number of equities research analysts have issued reports on FENC shares. HC Wainwright set a $18.00 target price on Fennec Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 21st. Zacks Investment Research lowered Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 28th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $15.00.
ILLEGAL ACTIVITY WARNING: “Fennec Pharmaceuticals (FENC) Issues Earnings Results” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4220307/fennec-pharmaceuticals-fenc-issues-earnings-results.html.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.